Register entry
Incyte Corporation
- Registered sites
- 0
- Drug products
- 22
- Live patents
- 273
- Countries
- 0
- Base
- Unknown
Sites
Facilities
0No registered facilities
This company holds drug listings or approvals but operates no registered establishment of its own, which is normal for an NDA holder that outsources manufacturing.
Exclusivity
Patents
273Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| JAKAFI | RUXOLITINIB PHOSPHATE | Dec 2026 |
| JAKAFI | RUXOLITINIB PHOSPHATE | Jun 2027 |
| JAKAFI | RUXOLITINIB PHOSPHATE | Dec 2027 |
| JAKAFI | RUXOLITINIB PHOSPHATE | Jun 2028 |
| JAKAFI | RUXOLITINIB PHOSPHATE | Jun 2028 |
| JAKAFI | RUXOLITINIB PHOSPHATE | Dec 2028 |
| JAKAFI XR | RUXOLITINIB PHOSPHATE | Dec 2026 |
| JAKAFI XR | RUXOLITINIB PHOSPHATE | Dec 2027 |
| JAKAFI XR | RUXOLITINIB PHOSPHATE | Jun 2028 |
| JAKAFI XR | RUXOLITINIB PHOSPHATE | Jun 2028 |
| JAKAFI XR | RUXOLITINIB PHOSPHATE | Dec 2028 |
| JAKAFI XR | RUXOLITINIB PHOSPHATE | Nov 2033 |
| JAKAFI XR | RUXOLITINIB PHOSPHATE | Jan 2034 |
| JAKAFI XR | RUXOLITINIB PHOSPHATE | May 2034 |
| JAKAFI XR | RUXOLITINIB PHOSPHATE | Jul 2034 |
| OPZELURA | RUXOLITINIB PHOSPHATE | Dec 2026 |
| OPZELURA | RUXOLITINIB PHOSPHATE | Jun 2027 |
| OPZELURA | RUXOLITINIB PHOSPHATE | Dec 2027 |
| OPZELURA | RUXOLITINIB PHOSPHATE | Jun 2028 |
| OPZELURA | RUXOLITINIB PHOSPHATE | Jun 2028 |
| OPZELURA | RUXOLITINIB PHOSPHATE | Dec 2028 |
| OPZELURA | RUXOLITINIB PHOSPHATE | May 2031 |
| OPZELURA | RUXOLITINIB PHOSPHATE | Nov 2031 |
| OPZELURA | RUXOLITINIB PHOSPHATE | Jun 2040 |
| OPZELURA | RUXOLITINIB PHOSPHATE | Jul 2040 |
| OPZELURA | RUXOLITINIB PHOSPHATE | Sept 2040 |
| OPZELURA | RUXOLITINIB PHOSPHATE | May 2041 |
| PEMAZYRE | PEMIGATINIB | Apr 2034 |
| PEMAZYRE | PEMIGATINIB | Jan 2035 |
| PEMAZYRE | PEMIGATINIB | May 2039 |
| PEMAZYRE | PEMIGATINIB | Aug 2040 |
| PEMAZYRE | PEMIGATINIB | Oct 2040 |
Catalogue
Marketed products
22Showing 22 of 22.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| JAKAFI | ruxolitinib | TABLET | NDA |
| JAKAFI | ruxolitinib | TABLET | NDA |
| JAKAFI | ruxolitinib | TABLET | NDA |
| JAKAFI | ruxolitinib | TABLET | NDA |
| JAKAFI | ruxolitinib | TABLET | NDA |
| JAKAFI XR | ruxolitinib | TABLET, EXTENDED RELEASE | NDA |
| JAKAFI XR | ruxolitinib | TABLET, EXTENDED RELEASE | NDA |
| JAKAFI XR | ruxolitinib | TABLET, EXTENDED RELEASE | NDA |
| JAKAFI XR | ruxolitinib | TABLET, EXTENDED RELEASE | NDA |
| JAKAFI XR | ruxolitinib | TABLET, EXTENDED RELEASE | NDA |
| MONJUVI | Tafasitamab-cxix | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | BLA |
| MONJUVI | Tafasitamab-cxix | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | BLA |
| NIKTIMVO | axatilimab-csfr | INJECTION | BLA |
| NIKTIMVO | axatilimab-csfr | INJECTION | BLA |
| NIKTIMVO | axatilimab-csfr | INJECTION | BLA |
| NIKTIMVO | axatilimab-csfr | INJECTION | BLA |
| NIKTIMVO | axatilimab-csfr | INJECTION | BLA |
| OPZELURA | ruxolitinib | CREAM | NDA |
| PEMAZYRE | pemigatinib | TABLET | NDA |
| PEMAZYRE | pemigatinib | TABLET | NDA |
| PEMAZYRE | pemigatinib | TABLET | NDA |
| ZYNYZ | retifanlimab-dlwr | INJECTION | BLA |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.